Form 4: Biodesix CCO O'Kane Reports RSU Vesting, Tax-Related Stock Sale

Biodesix Chief Commercial Officer Kieran O'Kane reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Kieran O'Kane, Chief Commercial Officer of Biodesix Inc. (BDSX), reported transactions related to his beneficial ownership.
• On February 9, 2026, O'Kane acquired 1,600 shares of common stock through the vesting of restricted stock units (RSUs).
• This acquisition included 73 RSUs that vested quarterly from February 8, 2022, and 1,527 RSUs that vest annually from February 8, 2023.
• On February 10, 2026, O'Kane disposed of 584 shares of common stock at a weighted average price of $10.0841 per share.
• This sale was an automatic transaction to cover tax obligations upon the vesting of the RSUs.
• Following these transactions, O'Kane beneficially owns 8,885 shares of Biodesix common stock.
• The RSU numbers have been adjusted to reflect a one-for-twenty reverse stock split effective September 15, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a net reduction in shares, the underlying RSU vesting indicates continued compensation and commitment, with the sale being a standard tax-related action rather than a discretionary divestment.

Positives

• Vesting of Restricted Stock Units indicates continued employment and achievement of performance or time-based milestones.
• The acquisition of 1,600 shares increases the officer's direct stake in the company, prior to the tax-related sale.

Negatives

• A net reduction in beneficial ownership from 9,469 shares to 8,885 shares after the tax-related sale.
• The sale of 584 shares, even for tax purposes, reduces the officer's direct equity holding.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those related to RSU vesting and subsequent tax-related sales, are common across the biotechnology and diagnostics industry. These transactions typically reflect compensation structures rather than a change in management's fundamental view of the company's prospects, especially when the sale is explicitly for tax purposes.

Related Party Transactions

• The reported transactions involve an officer of Biodesix Inc. (Kieran O'Kane) and the company's securities, which are inherently related-party dealings under SEC regulations.
• The vesting of Restricted Stock Units (RSUs) is part of the officer's compensation package.
• The sale of shares to cover taxes upon RSU vesting is a direct consequence of this compensation.

Stakeholder Impact

• Shareholders: The transactions provide transparency into insider holdings and compensation practices. The tax-related sale is a routine event and unlikely to significantly impact shareholder sentiment.
• Employees: The RSU vesting demonstrates the company's compensation structure for key personnel, potentially influencing employee morale and retention.

Key Dates

Recommendation

The filing details routine insider transactions related to compensation (RSU vesting) and subsequent tax obligations. There are no discretionary sales or purchases that would indicate a change in management's outlook or warrant a strong buy/sell recommendation. The information is neutral for the stock's fundamental valuation, thus a 'hold' recommendation is appropriate.

Keywords

Biodesix, BDSX, Kieran O'Kane, Chief Commercial Officer, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Obligations, Beneficial Ownership, Reverse Stock Split